Viusid

DIETARY_SUPPLEMENT6 trials

Sponsors

Catalysis SL, Catalysis Laboratories, SL.

Conditions

Acute Fever of Viral EtiologyAntisepticChronic Hepatitis CChronic Inflammatory SyndromeChronic Kidney DiseaseCovid19Immune SystemImmunomodulator

Phase 2

Viusid in Adults With Acute Fever of Viral Etiology

CompletedNCT01008007

Catalysis SLAcute Fever of Viral Etiology

Start: 2009-09-30End: 2010-05-31Target: 200Updated: 2010-05-18

Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19

CompletedNCT04701502

Catalysis SLAntiseptic, Covid19, Immune System +3

Start: 2020-11-09End: 2021-02-15Updated: 2021-10-21

Effect and safety of the use of Viusid® on the quality of life of patients with Chronic Kidney Disease on Hemodialysis.

Active, not recruitingRPCEC00000420

Catalysis Laboratories, SL.Chronic Kidney Disease

Start: 2023-04-05Target: 60Updated: 2026-08-10

Phase 3

Efficacy and Safety of Viusid in Patients With Nonalcoholic Steatohepatitis

CompletedNCT00509418

Catalysis SLNonalcoholic Steatohepatitis

Start: 2007-02-28End: 2007-09-30Updated: 2009-01-12

Antioxidant and Immunomodulator Properties of Viusid in Patients With Chronic Hepatitis C

CompletedNCT00778843

Catalysis SLChronic Hepatitis C

Start: 2008-10-31End: 2009-05-31Updated: 2012-05-04

Viusid Administration in Subjects With Chronic Inflammatory Syndrome Under Hemodialysis Treatment

SuspendedNCT00978224

Catalysis SLChronic Inflammatory Syndrome

Start: 2009-10-31End: 2011-09-30Target: 152Updated: 2010-07-07